RVNC - Revance climbs 14% as FDA approves facial injectable for frown lines

• The shares of Revance Therapeutics ( NASDAQ: RVNC ), a biotech focused on neuromodulators, added ~14% in the pre-market trading Thursday after the company announced the FDA approval of Daxxify injection for the temporary improvement of moderate to severe frown lines.
• The decision marks the RVNC’s first FDA approval and allows the company to access the growing U.S. market for facial injectables worth $3.2B.
• The FDA approval is based on data from SAKURA Phase 3 clinical trial program, which involved over 2,700 patients and nearly 4,200 treatments.
• “We are excited to be launching DAXXIFY™ shortly with an early training and education program at our world-class headquarters and experience center in Nashville, followed by a broader commercial launch,” President of RVNC Dustin S. Sjuts said ahead of the conference call today at 8:00 a.m. ET.

For further details see: